ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle [Seeking Alpha]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
Anktiva faces tough competition from existing treatments and promising therapies in the pipeline. ImmunityBio has financial resources for the short-term, but long-term financial health remains uncertain. Investment recommendation: Sell ImmunityBio due to high valuation amidst competitive and financial challenges. Introduction ImmunityBio, Inc. NASDAQ: IBRX announced today that their IL-15 immunotherapy, Anktiva, was approved by the FDA for the treatment of "BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)." This followed a Complete Response Letter [CRL] from May 2023 citing deficiencies in third-party Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio partners with Serum Institute for BCG vaccines [Yahoo! Finance]Yahoo! Finance
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types [Yahoo! Finance]Yahoo! Finance
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesBusiness Wire
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationBusiness Wire
IBRX
Earnings
- 8/8/23 - Miss
IBRX
Sec Filings
- 5/3/24 - Form EFFECT
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- IBRX's page on the SEC website